Area of research
Neurology · Immunology
Research interest
Research interests include Vascular Malformations Diagnosis and Treatment, Intracerebral and Subarachnoid Hemorrhage Research, Intracranial Aneurysms: Treatment and Complications, and Immune Response and Inflammation.
Transcriptomic signatures of individual cell types in cerebral cavernous malformation
mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma
Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu disease)
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling
Inflammatory Mechanisms in a Neurovascular Disease: Cerebral Cavernous Malformation
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation
Perfusion and Permeability<scp>MRI</scp>Predicts Future Cavernous Angioma Hemorrhage and Growth
Novel Murine Models of Cerebral Cavernous Malformations
Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican
Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models
Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu
Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive <i>Pdcd10/Ccm3</i> Disease
Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes
Biomarkers of cavernous angioma with symptomatic hemorrhage
Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations
A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease
Phantom validation of quantitative susceptibility and dynamic contrast‐enhanced permeability MR sequences across instruments and sites
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH)
Phenotypic characterization of murine models of cerebral cavernous malformations
Endothelial TLR4 and the microbiome drive cerebral cavernous malformations
Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations